MediMix aims to bring high value medical information to Belgian healthcare professionals via multiple channels. Our team covers congresses and symposia all over the world, particularly in the hematology domain. In collaboration with Belgian and international experts, we bring the newest data to Belgian physicians.
During the 2025 ICML meeting, Dr Gabriel Brisou presented French real-world data of DLBCL patients treated with 2nd line liso-cel in the French DESCAR-T registry.
At ICML 2025, Prof Caron Jacobson presented a poster on a pilot study evaluating axicabtagene ciloleucel (axi-cel) in patients with primary and secondary CNS lymphoma, primarily in the second line
During the 2025 ICML meeting, Prof Olalekan Oluwole shared the results of a systematic literature review and meta-analysis evaluating real-world outcomes for patients with relapsed/refractory mantle cell lymphoma (R/R MCL)
The SEQUOIA Arm D study explored the combination of zanubrutinib and venetoclax for untreated CLL/SLL patients, including those with abnormal TP53. Both normal and abnormal TP53 cohorts showed high response
Dr Allison Winter presented at ICML 2025 data that highlight a collaboration between KITE and the CIBMTR data registry, examining the outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of
At ICML 2025 in Lugano, new data from the phase 2 TRANSCEND study for lisocabtagene maraleucel (liso-cel) CAR-T cell therapy for indolent lymphoma were communicated.
At the ICML meeting, the results from the S1826 study were discussed, which focused on patients with advanced-stage Hodgkin Lymphoma (HL). This randomised phase 3 study compared brentuximab vedotin plus
During this ICML, Dr Bailly and Dr Johannes Düll had an interesting discussion around the combination of tafasitamab and lenalidomide, an FDA and EMA-approved treatment for relapsed or refractory diffuse
